10x Genomics
290 hedge funds and large institutions have $3.89B invested in 10x Genomics in 2024 Q1 according to their latest regulatory filings, with 60 funds opening new positions, 113 increasing their positions, 77 reducing their positions, and 42 closing their positions.
266% more call options, than puts
Call options by funds: $14.3M | Put options by funds: $3.9M
47% more repeat investments, than reductions
Existing positions increased: 113 | Existing positions reduced: 77
43% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 42
5% more funds holding
Funds holding: 275 → 290 (+15)
2.24% more ownership
Funds ownership: 96.15% → 98.39% (+2.2%)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
31% less capital invested
Capital invested by funds: $5.6B → $3.89B (-$1.72B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$98.5M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$58.8M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$58.8M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$46.7M |
| 5 |
Millennium Management
New York
|
+$37.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$140M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$98.9M |
| 3 |
JP Morgan Chase
New York
|
-$61.3M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$40.8M |
| 5 |
SIM
SRS Investment Management
New York
|
-$38.3M |
TXG Hedge Fund Activity: Q1 2024 in Review
290 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q1 2024, worth a combined $3.89B — down 31% from $5.6B a quarter earlier.
Buyers outnumbered sellers: 60 funds opened new TXG positions and 42 closed out — a net gain of 18 holders — while 113 added to existing stakes and 77 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $98.5M. The largest seller was Morgan Stanley, cutting an estimated $140M.
- 290 institutional investors held 10x Genomics (TXG) as of Q1 2024, up from 275 in Q4 2023.
- Funds reported $3.89B of 10x Genomics stock for Q1 2024, down 31% quarter-over-quarter.
- 60 funds opened new 10x Genomics positions in Q1 2024 and 42 closed out, a net change of +18 holders.
- The largest 10x Genomics buyer in Q1 2024 was ARK Investment Management, an estimated $98.5M added.
- The largest 10x Genomics seller in Q1 2024 was Morgan Stanley, an estimated $140M sold.
Based on aggregated 13F filings for Q1 2024.